Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SARS CoV 2 Infection clinical trials
11 of 29 indexed SARS CoV 2 Infection trials are currently recruiting.
29 US clinical trials · 11 currently recruiting
SARS CoV 2 Infection is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is BioNTech SE, running 6 of these trials.
The research picture
SARS CoV 2 Infection has 29 registered US clinical trials, 11 of them open to new participants right now, about 38% of the total.
- 11
- recruiting participants now
- 38%
- of trials open to enrollment
- 6
- in Phase 3–4 (later-stage)
- 6
- top sponsor: BioNTech SE
Active & Recent Trials
29 total, page 1 of 1
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
BioNTech SE
NCT07300839
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Boston University
NCT06168019
COVID-19 Transmission and Morbidity in Malawi
Boston University
NCT05973084
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Columbia University
NCT05467930
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Wes Ely
NCT06631287
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
NYU Langone Health
NCT05292274
Exercise in Child Health
University of California, Irvine
NCT05359991
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Kara Chew
NCT06810934
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
Vanderbilt University Medical Center
NCT05421208
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Vanderbilt University Medical Center
NCT07189936
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
Children's National Research Institute
NCT05141058
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
Medicago
NCT04636697
Understanding the Long-term Impact of COVID on Children and Families
NYU Langone Health
NCT05172011
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
BioNTech SE
NCT07069309
Safety and Immunogenicity of NVX-CoV2705
Sanofi
NCT07079670
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Novavax
NCT06633835
Post Acute Sequelae of COVID-19
Vanderbilt University Medical Center
NCT04964115
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
Columbia University
NCT05467917
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
BioNTech SE
NCT07222384
Transplacental Transmission of RSV (TTRSV)
Tulane University
NCT05443607
Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
San Diego State University
NCT05697068
Pancoronavirus Vaccine Study in Healthy Adults
Duke University
NCT06950177
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
BioNTech SE
NCT04368728
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
BioNTech SE
NCT05004181
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
NCT05997290
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
University of Washington
NCT05074719
Safe and Healthy Schools
University of Wisconsin, Madison
NCT05105789
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
The University of Texas Health Science Center at San Antonio
NCT04818216
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
Johns Hopkins University
NCT04377672
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the SARS CoV 2 Infection Trial Landscape
29 indexed SARS CoV 2 Infection studies · 11 recruiting (38%).
Phase mix: 6 late (III/IV) vs 10 early (I/II).
Top sponsor: BioNTech SE (6 trials), 9 others listed. 29 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for SARS CoV 2 Infection?
PlainTrial tracks 29 US clinical trials for SARS CoV 2 Infection, of which 11 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for SARS CoV 2 Infection?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.